Table 2. PD-1 and PD-L1 expression in immune cell subsets at the end of in vitro stimulation with peptides in the absence of anti-PD-L1 treatment.
| Subsets measured | HLA | CEFT |
|---|---|---|
| CD8 PD-L1+ | 0.82 (0.6–1.42) | 1.65 (1.07–2.32) |
| CD8 PD-1+ | 0.46 (0.12–0.98) | 1.18 (0.4–2.17) |
| CD4 PD-L1+ | 0.72 (0.55–0.89) | 1.17 (1.11–1.46) |
| CD4 PD-1+ | 1.68 (0.8–2.31) | 2.52 (2.11–2.89) |
| B cell PD-L1+ | 3.1 (2.75–11.3) | 11.3 (5.63–17.8) |
| B cell PD-1+ | 1.5 (0.9–5.48) | 7.45 (3.75–9.58) |
| CD8 IFNγ+ PD-L1+ | 0.01 (0.0–0.02) | 0.25 (0.1–0.57) |
| CD8 IFNγ+ PD-1+ | 0.0 (0.0–0.03) | 1.15 (0.08–1.43) |
| CD8 CD107a+ PD-L1+ | 0.03 (0.01–0.06) | 0.23 (0.1–0.36) |
| CD8 CD107a+ PD-1+ | 0.01 (0.0–0.1) | 0.22 (0.1–1.19) |
| CD8 CD107a+ IFNγ+ PD-L1+ | 0.0 (0.0–0.02) | 0.14 (0.05–0.21) |
| CD8 CD107a+ IFNγ+ PD-1+ | 0.0 (0.0–0.02) | 0.05 (0.03–0.71) |
Abbreviations: HLA, human leukocyte antigen; PBMC, peripheral blood mononuclear cell; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.
PBMCs from healthy donors (n=4), stimulated with CEFT or HLA, as described in Supplementary Figure 3a (without avelumab), were harvested on day 12 of the stimulation assay and analyzed by flow cytometry for PD-1 (clone MIH4) and PD-L1 (clone MIH1) expression. Values represent the median percentage of PBMCs that were CD8+, CD4+ or CD19+ (B cells) and expressed PD-1 or PD-L1, or activated CD8+ T cells (IFNγ+, CD107a+ and CD107a+ IFNγ+) that expressed PD-1 or PD-L1 as a percentage of total CD8+ T lymphocytes. Interquartile ranges are indicated in parentheses.